Alfredo Fusco

Q: What Schools Are Affiliated With Alfredo Fusco

Alfredo Fusco is affiliated with the following schools: University of California, Berkeley, Stanford University, University of Naples Federico II

Alfredo Fusco's AcademicInfluence.com Rankings

Alfredo Fusco

Computer Science

#5212

World Rank

#5506

Historical Rank

Computational Linguistics

#670

World Rank

#682

Historical Rank

Machine Learning

#1294

World Rank

#1314

Historical Rank

Artificial Intelligence

#1528

World Rank

#1557

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Alfredo Fusco's Degrees

PhD Computer Science Stanford University
Masters Computer Science University of California, Berkeley
Bachelors Computer Science University of California, Berkeley

Similar Degrees You Can Earn

Why Is Alfredo Fusco Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Alfredo Fusco's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. (2003) (1023)
PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas (1990) (954)
Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B (1995) (838)
Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27Kip1 by PKB/Akt-mediated phosphorylation in breast cancer (2002) (749)
Roles of HMGA proteins in cancer (2007) (662)
ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. (2002) (611)
Regulation of thyroid cell proliferation by TSH and other factors: a critical evaluation of in vitro models. (2001) (442)
MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. (2007) (435)
Bioactive IL-18 expression is up-regulated in Crohn's disease. (1999) (424)
MicroRNA deregulation in human thyroid papillary carcinomas. (2006) (418)
A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases (1987) (403)
Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma. (1994) (376)
Specific microRNAs are downregulated in human thyroid anaplastic carcinomas (2007) (363)
Increased BDNF promoter methylation in the Wernicke area of suicide subjects. (2010) (359)
Mutation of the PIK3CA gene in anaplastic thyroid cancer. (2005) (336)
RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. (1998) (329)
The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. (2005) (322)
High level expression of the HMGI (Y) gene during embryonic development. (1996) (315)
One- and two-step transformations of rat thyroid epithelial cells by retroviral oncogenes (1987) (290)
The RET receptor: function in development and dysfunction in congenital malformation. (2001) (288)
High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma. (1989) (282)
RET/PTC oncogene activation is an early event in thyroid carcinogenesis. (1995) (270)
The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids. (1998) (260)
Expression of the RET/PTC Fusion Gene as a Marker for Papillary Carcinoma in Hashimoto's Thyroiditis (1997) (255)
High prevalence of RET/PTC rearrangements in Ukrainian and Belarussian post-Chernobyl thyroid papillary carcinomas: a strong correlation between RET/PTC3 and the solid-follicular variant. (1999) (255)
Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1 oncogene in transgenic mice. (1996) (249)
HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity. (2006) (248)
The ret proto-oncogene is consistently expressed in human pheochromocytomas and thyroid medullary carcinomas. (1990) (246)
Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors (2004) (238)
Characterization of an inversion on the long arm of chromosome 10 juxtaposing D10S170 and RET and creating the oncogenic sequence RET/PTC. (1992) (235)
Frequent activation of ret protooncogene by fusion with a new activating gene in papillary thyroid carcinomas. (1994) (232)
Nuclear phosphoproteins HMGA and their relationship with chromatin structure and cancer (2004) (223)
The expression of a truncated HMGI-C gene induces gigantism associated with lipomatosis. (1999) (213)
Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas (2002) (211)
Inhibition of HMGI-C protein synthesis suppresses retrovirally induced neoplastic transformation of rat thyroid cells (1995) (210)
Lack of the architectural factor HMGA1 causes insulin resistance and diabetes in humans and mice (2005) (209)
Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation. (2005) (204)
The expression of the high mobility group HMGI (Y) proteins correlates with the malignant phenotype of human thyroid neoplasias. (1995) (198)
RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma. (2006) (198)
Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NFκB p65 protein expression (1997) (197)
DNA Damage, Homology-Directed Repair, and DNA Methylation (2007) (196)
RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture. (2006) (187)
Minireview: RET: normal and abnormal functions. (2004) (176)
Molecular Mechanisms of RET Activation in Human Cancer (2002) (169)
A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma. (2007) (166)
5-Aza-2'-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias. (1984) (165)
Neoplastic transformation of rat thyroid cells requires the junB and fra‐1 gene induction which is dependent on the HMGI‐C gene product (1997) (163)
Human colorectal carcinomas express high levels of high mobility group HMGI(Y) proteins. (1996) (160)
Adenovirus-mediated suppression of HMGI(Y) protein synthesis as potential therapy of human malignant neoplasias. (2000) (156)
Elevated levels of a specific class of nuclear phosphoproteins in cells transformed with v‐ras and v‐mos oncogenes and by cotransfection with c‐myc and polyoma middle T genes. (1987) (154)
Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma. (1998) (154)
PTEN expression is reduced in a subset of sporadic thyroid carcinomas: evidence that PTEN-growth suppressing activity in thyroid cancer cells is mediated by p27kip1 (2000) (153)
RET/PTC Activation in Hyalinizing Trabecular Tumors of the Thyroid (2000) (148)
Transgenic mice overexpressing the wild-type form of the HMGA1 gene develop mixed growth hormone/prolactin cell pituitary adenomas and natural killer cell lymphomas (2005) (148)
HMGA and cancer. (2010) (147)
The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes. (2002) (146)
Docking Protein FRS2 Links the Protein Tyrosine Kinase RET and Its Oncogenic Forms with the Mitogen-Activated Protein Kinase Signaling Cascade (2001) (145)
Molecular heterogeneity of RET loss of function in Hirschsprung's disease. (1996) (145)
Assessment of RET/PTC oncogene activation and clonality in thyroid nodules with incomplete morphological evidence of papillary carcinoma: a search for the early precursors of papillary cancer. (2002) (144)
Overexpressed cyclin D3 contributes to retaining the growth inhibitor p27 in the cytoplasm of thyroid tumor cells. (1999) (143)
The TRK and RET tyrosine kinase oncogenes cooperate with ras in the neoplastic transformation of a rat thyroid epithelial cell line. (1993) (143)
Signalling of the Ret receptor tyrosine kinase through the c-Jun NH2-terminal protein kinases (JNKs): evidence for a divergence of the ERKs and JNKs pathways induced by Ret (1998) (139)
Inhibitory Effects of Peroxisome Proliferator-Activated Receptor γ on Thyroid Carcinoma Cell Growth (2002) (139)
Altered microRNA expression profile in human pituitary GH adenomas: down-regulation of miRNA targeting HMGA1, HMGA2, and E2F1. (2012) (139)
Upregulation of miR-21 by Ras in vivo and its role in tumor growth (2011) (136)
Negative Regulation of BRCA1 Gene Expression by HMGA1 Proteins Accounts for the Reduced BRCA1 Protein Levels in Sporadic Breast Carcinoma (2003) (135)
Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas (2004) (134)
Analysis of the HMGI nuclear proteins in mouse neoplastic cells induced by different procedures. (1989) (134)
Description of a human papillary thyroid carcinoma cell line. Morphologic study and expression of tumoral markers (1994) (132)
Truncated and chimeric HMGI-C genes induce neoplastic transformation of NIH3T3 murine fibroblasts (1998) (132)
Developmental expression of the RET protooncogene. (1994) (131)
Expression of HMGI(Y) proteins in squamous intraepithelial and invasive lesions of the uterine cervix. (1998) (128)
Gene rearrangement and Chernobyl related thyroid cancers (2000) (126)
An epidermal growth factor receptor/ret chimera generates mitogenic and transforming signals: evidence for a ret-specific signaling pathway (1994) (125)
Role of the high mobility group A proteins in human lipomas. (2001) (125)
Multiple mechanisms of interference between transformation and differentiation in thyroid cells (1992) (121)
Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2). (2003) (121)
Rat Protein Tyrosine Phosphatase η Suppresses the Neoplastic Phenotype of Retrovirally Transformed Thyroid Cells through the Stabilization of p27Kip1 (2000) (120)
An increased high-mobility group A2 expression level is associated with malignant phenotype in pancreatic exocrine tissue (2003) (119)
Loss of the tumor suppressor gene PTEN marks the transition from intratubular germ cell neoplasias (ITGCN) to invasive germ cell tumors (2005) (118)
Changes in nuclear proteins on transformation of rat epithelial thyroid cells by a murine sarcoma retrovirus. (1985) (116)
RET activation and clinicopathologic features in poorly differentiated thyroid tumors. (2002) (115)
Complex regulation of the cyclin-dependent kinase inhibitor p27kip1 in thyroid cancer cells by the PI3K/AKT pathway: regulation of p27kip1 expression and localization. (2005) (115)
UbcH10 overexpression may represent a marker of anaplastic thyroid carcinomas (2005) (114)
Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteines (1998) (114)
The TRK-T1 fusion protein induces neoplastic transformation of thyroid epithelium (2000) (112)
Pancreatic duct cell carcinomas express high levels of high mobility group I(Y) proteins. (2000) (111)
High Mobility Group A Proteins as Tumor Markers (2015) (111)
Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma. (2002) (111)
MiR-1 is a tumor suppressor in thyroid carcinogenesis targeting CCND2, CXCR4, and SDF-1alpha. (2011) (111)
Familial cancer associated with a polymorphism in ARLTS1. (2005) (107)
Haploinsufficiency of the Hmga1 gene causes cardiac hypertrophy and myelo-lymphoproliferative disorders in mice. (2006) (107)
Deregulation of microRNA expression in thyroid neoplasias (2014) (107)
The RET/PTC oncogene is frequently activated in oncocytic thyroid tumors (Hurthle cell adenomas and carcinomas), but not in oncocytic hyperplastic lesions. (2002) (106)
Down-regulation of the miR-25 and miR-30d contributes to the development of anaplastic thyroid carcinoma targeting the polycomb protein EZH2. (2012) (105)
Deregulation of microRNA expression in follicular-cell-derived human thyroid carcinomas. (2010) (105)
Upregulation of the angiogenic factors PlGF, VEGF and their receptors (Flt-1, Flk-1/KDR) by TSH in cultured thyrocytes and in the thyroid gland of thiouracil-fed rats suggest a TSH-dependent paracrine mechanism for goiter hypervascularization (1997) (104)
Onset of natural killer cell lymphomas in transgenic mice carrying a truncated HMGI-C gene by the chronic stimulation of the IL-2 and IL-15 pathway (2001) (103)
High-mobility group A1 inhibits p53 by cytoplasmic relocalization of its proapoptotic activator HIPK2. (2007) (102)
HMGA proteins up-regulate CCNB2 gene in mouse and human pituitary adenomas. (2009) (102)
The different RET-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype. (1997) (102)
HMGA1 and HMGA2 protein expression in mouse spermatogenesis (2002) (101)
Reexpression of thyroid peroxidase in a derivative of an undifferentiated thyroid carcinoma cell line by introduction of wild-type p53. (1996) (101)
The High Mobility Group A2 gene is amplified and overexpressed in human prolactinomas. (2002) (99)
Determination of high mobility group I(Y) expression level in colorectal neoplasias: a potential diagnostic marker. (1999) (98)
CBX7 is a tumor suppressor in mice and humans. (2012) (96)
Thymosin β-10 Gene Overexpression Is a General Event in Human Carcinogenesis (1999) (96)
Critical Role of the HMGI(Y) Proteins in Adipocytic Cell Growth and Differentiation (2001) (95)
Downregulation of HMGA-targeting microRNAs has a critical role in human pituitary tumorigenesis (2012) (95)
Dysfunction of the RET receptor in human cancer. (2004) (94)
HMGIY is the target of 6p21.3 rearrangements in various benign mesenchymal tumors (1998) (94)
High mobility group I (Y) proteins bind HIPK2, a serine-threonine kinase protein which inhibits cell growth (2001) (93)
Glial cell line-derived neutrotrophic factor and neurturin can act as paracrine growth factors stimulating DNA synthesis of Ret-expressing spermatogonia. (2000) (93)
Thyroid cell transformation requires the expression of the HMGA1 proteins (2002) (92)
A Novel Member of the BTB/POZ Family, PATZ, Associates with the RNF4 RING Finger Protein and Acts as a Transcriptional Repressor* (2000) (92)
Tyrosine 1062 of RET-MEN2A mediates activation of Akt (protein kinase B) and mitogen-activated protein kinase pathways leading to PC12 cell survival. (2000) (92)
Phosphorylation of high-mobility group protein A2 by Nek2 kinase during the first meiotic division in mouse spermatocytes. (2003) (90)
Akt-Dependent T198 Phosphorylation of Cyclin-Dependent Kinase Inhibitor p27kip1 in Breast Cancer (2004) (87)
HMGA1 protein over-expression is a frequent feature of epithelial ovarian carcinomas. (2003) (87)
The loss of the CBX7 gene expression represents an adverse prognostic marker for survival of colon carcinoma patients. (2010) (86)
miR-23b and miR-130b expression is downregulated in pituitary adenomas (2014) (85)
The beta-catenin axis integrates multiple signals downstream from RET/papillary thyroid carcinoma leading to cell proliferation. (2009) (84)
A miRNA signature associated with human metastatic medullary thyroid carcinoma. (2013) (83)
Chromobox protein homologue 7 protein, with decreased expression in human carcinomas, positively regulates E-cadherin expression by interacting with the histone deacetylase 2 protein. (2009) (83)
Molecular profile of hyalinizing trabecular tumours of the thyroid: high prevalence of RET/PTC rearrangements and absence of B-raf and N-ras point mutations. (2005) (82)
Loss of the CBX7 protein expression correlates with a more aggressive phenotype in pancreatic cancer. (2010) (82)
High Mobility Group A1 (HMGA1) proteins interact with p53 and inhibit its apoptotic activity (2006) (80)
Transformation of thyroid epithelium is associated with loss of c-kit receptor. (1995) (79)
TAZ/WWTR1 is overexpressed in papillary thyroid carcinoma. (2011) (78)
HMGA1 and HMGA2 protein expression correlates with advanced tumour grade and lymph node metastasis in pancreatic adenocarcinoma (2012) (78)
Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B. (2001) (77)
Expression of HMGI-C and HMGI(Y) in ordinary lipoma and atypical lipomatous tumors: immunohistochemical reactivity correlates with karyotypic alterations. (1997) (77)
Identification of a New Pathway for Tumor Progression: MicroRNA-181b Up-Regulation and CBX7 Down-Regulation by HMGA1 Protein. (2010) (77)
The insulin receptor substrate (IRS)-1 recruits phosphatidylinositol 3-kinase to Ret: evidence for a competition between Shc and IRS-1 for the binding to Ret (2001) (76)
Iodide symporter gene expression in normal and transformed rat thyroid cells. (1999) (75)
RET expression in papillary thyroid cancer from patients irradiated in childhood for benign conditions. (2002) (75)
The tyrosine phosphatase PTPRJ/DEP-1 genotype affects thyroid carcinogenesis (2004) (75)
Identification of the product of two oncogenic rearranged forms of the RET proto-oncogene in papillary thyroid carcinomas. (1992) (74)
Conditional expression of RET/PTC induces a weak oncogenic drive in thyroid PCCL3 cells and inhibits thyrotropin action at multiple levels. (2003) (74)
PATZ1 gene has a critical role in the spermatogenesis and testicular tumours (2008) (74)
Molecular defects in thyroid carcinomas: role of the RET oncogene in thyroid neoplastic transformation. (1995) (74)
HMGA1 Protein Overexpression in Human Breast Carcinomas (2004) (73)
Block in the expression of differentiation markers of rat thyroid epithelial cells by transformation with Kirsten murine sarcoma virus. (1982) (73)
Expression of galectin‐1 in normal human thyroid gland and in differentiated and poorly differentiated thyroid tumors (1995) (73)
Somatostatin inhibits PC Cl3 thyroid cell proliferation through the modulation of phosphotyrosine activity. Impairment of the somatostatinergic effects by stable expression of E1A viral oncogene. (1996) (73)
Retinoic acid induces neuronal differentiation of embryonal carcinoma cells by reducing proteasome-dependent proteolysis of the cyclin-dependent inhibitor p27. (2000) (72)
HMGA1 pseudogenes as candidate proto-oncogenic competitive endogenous RNAs (2014) (72)
Oncogenic alterations in papillary thyroid cancers of young patients. (2012) (71)
Thyroid targeting of the N-ras(Gln61Lys) oncogene in transgenic mice results in follicular tumors that progress to poorly differentiated carcinomas (2006) (70)
MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1 (2015) (70)
Restoration of receptor-type protein tyrosine phosphatase eta function inhibits human pancreatic carcinoma cell growth in vitro and in vivo. (2004) (69)
Genetic Alterations in Thyroid Carcinoma Associated with Familial Adenomatous Polyposis: Clinical Implications and Suggestions for Early Detection (1998) (69)
Loss of the CBX7 gene expression correlates with a highly malignant phenotype in thyroid cancer. (2008) (69)
UbcH10 is overexpressed in malignant breast carcinomas. (2007) (69)
TACC3 mediates the association of MBD2 with histone acetyltransferases and relieves transcriptional repression of methylated promoters (2013) (69)
Regulation of BRCA1 Transcription by Specific Single-Stranded DNA Binding Factors (2003) (68)
HMGA2 mRNA expression correlates with the malignant phenotype in human thyroid neoplasias. (2008) (68)
Point Mutation of the RetProto-oncogene in the TT Human Medullary Thyroid Carcinoma Cell Line (1995) (68)
ONYX-015, an E1B gene-defective adenovirus, induces cell death in human anaplastic thyroid carcinoma cell lines. (2002) (66)
Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation (2010) (65)
Loss of Hmga1 gene function affects embryonic stem cell lymphohematopoietic differentiation (2003) (64)
Reduced E-cadherin expression contributes to the loss of p27kip1-mediated mechanism of contact inhibition in thyroid anaplastic carcinomas. (2005) (64)
Increase in AP-1 activity is a general event in thyroid cell transformation in vitro and in vivo (1998) (64)
Enhancer of zeste homolog 2 overexpression has a role in the development of anaplastic thyroid carcinomas. (2011) (64)
HMGA1 silencing restores normal stem cell characteristics in colon cancer stem cells by increasing p53 levels (2014) (64)
siRNA nanoformulation against the Ret/PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinoma (2007) (64)
Cloning and molecular characterization of a novel gene strongly induced by the adenovirus E1A gene in rat thyroid cells (2003) (64)
The Expression of the Phosphotyrosine Phosphatase DEP-1/PTPη Dictates the Responsivity of Glioma Cells to Somatostatin Inhibition of Cell Proliferation* (2004) (64)
An adenovirus carrying the rat protein tyrosine phosphatase eta suppresses the growth of human thyroid carcinoma cell lines in vitro and in vivo. (2003) (64)
The oncogene associated with human papillary thyroid carcinoma (PTC) is assigned to chromosome 10 q11-q12 in the same region as multiple endocrine neoplasia type 2A (MEN2A). (1989) (63)
Cloning and characterization of H4 (D10S170), a gene involved in RET rearrangements in vivo. (1994) (63)
Induction of ETS-1 and ETS-2 transcription factors is required for thyroid cell transformation. (2001) (62)
Increased expression of the negative growth factor, galactoside-binding protein, gene in transformed thyroid cells and in human thyroid carcinomas. (1992) (62)
Thyroid cell transformation inhibits the expression of a novel rat protein tyrosine phosphatase. (1997) (62)
Detection of high‐mobility group proteins A1 and A2 represents a valid diagnostic marker in post‐pubertal testicular germ cell tumours (2008) (62)
HMGA2: A pituitary tumour subtype-specific oncogene? (2010) (62)
Expression of the RET/PTC1 oncogene impairs the activity of TTF-1 and Pax-8 thyroid transcription factors. (1998) (62)
Isolation of a SIR-like gene, SIR-T8, that is overexpressed in thyroid carcinoma cell lines and tissues (2002) (61)
High mobility group HMGI(Y) protein expression in human colorectal hyperplastic and neoplastic diseases (2001) (61)
The RFG oligomerization domain mediates kinase activation and re-localization of the RET/PTC3 oncoprotein to the plasma membrane (2001) (61)
Role of interleukin 8 in the genesis of acute respiratory distress syndrome through an effect on neutrophil apoptosis. (1998) (60)
RET/papillary thyroid carcinoma oncogenic signaling through the Rap1 small GTPase. (2007) (59)
Polycomb protein family member CBX7 plays a critical role in cancer progression. (2015) (59)
Point mutation of the RET proto-oncogene in the TT human medullary thyroid carcinoma cell line. (1995) (58)
Block of c-myc expression by antisense oligonucleotides inhibits proliferation of human thyroid carcinoma cell lines. (1996) (58)
High-mobility group A1 proteins regulate p53-mediated transcription of Bcl-2 gene. (2010) (58)
Fra‐1 promotes growth and survival in RAS‐transformed thyroid cells by controlling cyclin A transcription (2007) (58)
Tyrosines 1015 and 1062 are in vivo autophosphorylation sites in ret and ret-derived oncoproteins. (2000) (58)
Comparison of multiple forms of the high mobility group I proteins in rodent and human cells. Identification of the human high mobility group I-C protein. (1991) (57)
Dissociation between transformed and differentiated phenotype in rat thyroid epithelial cells after transformation with a temperature-sensitive mutant of the Kirsten murine sarcoma virus (1983) (57)
Modulation of in vivo growth of thyroid tumor-derived cell lines by sense and antisense vascular endothelial growth factor gene (1999) (57)
Chromatin and DNA methylation dynamics during retinoic acid-induced RET gene transcriptional activation in neuroblastoma cells (2010) (57)
Genetic ablation of Ptprj, a mouse cancer susceptibility gene, results in normal growth and development and does not predispose to spontaneous tumorigenesis. (2006) (57)
RNF4 is a growth inhibitor expressed in germ cells but not in human testicular tumors. (2001) (56)
Specific microRNAs are downregulated in human thyroid anaplastic carcinomas (2016) (55)
HIPK2 controls cytokinesis and prevents tetraploidization by phosphorylating histone H2B at the midbody. (2012) (55)
The homeodomain-interacting protein kinase 2 gene is expressed late in embryogenesis and preferentially in retina, muscle, and neural tissues. (2002) (55)
HMGA proteins promote ATM expression and enhance cancer cell resistance to genotoxic agents (2011) (55)
Hmga1/Hmga2 double knock-out mice display a “superpygmy” phenotype (2014) (55)
Regulation of p27Kip1 Protein Levels Contributes to Mitogenic Effects of the RET/PTC Kinase in Thyroid Carcinoma Cells (2004) (54)
Thymosin beta-10 gene overexpression is a general event in human carcinogenesis. (1999) (54)
Ret-mediated mitogenesis requires Src kinase activity. (1999) (53)
Insulin and TSH promote growth in size of PC Cl3 rat thyroid cells, possibly via a pathway different from DNA synthesis: comparison with FRTL-5 cells. (1999) (53)
FRA-1 expression in hyperplastic and neoplastic thyroid diseases. (2000) (53)
Inhibitory effects of peroxisome poliferator-activated receptor gamma on thyroid carcinoma cell growth. (2002) (53)
miR-191 down-regulation plays a role in thyroid follicular tumors through CDK6 targeting. (2011) (52)
Thymosin β-10 Gene Overexpression Correlated with the Highly Malignant Neoplastic Phenotype of Transformed Thyroid Cells in Vivo and in Vitro (1998) (52)
Ras-mediated apoptosis of PC CL 3 rat thyroid cells induced by RET/PTC oncogenes (2003) (52)
Simian virus 40-like DNA sequences in human papillary thyroid carcinomas (1998) (51)
HMGA1-pseudogene expression is induced in human pituitary tumors (2015) (51)
FRA-1 protein overexpression is a feature of hyperplastic and neoplastic breast disorders (2007) (51)
Key role of the cyclin-dependent kinase inhibitor p27kip1 for embryonal carcinoma cell survival and differentiation (1999) (50)
Downregulation of miR-410 targeting the cyclin B1 gene plays a role in pituitary gonadotroph tumors (2015) (50)
RPSAP52 lncRNA is overexpressed in pituitary tumors and promotes cell proliferation by acting as miRNA sponge for HMGA proteins (2019) (50)
Detection of RET oncogene activation in human papillary thyroid carcinomas by in situ hybridisation. (1992) (50)
Involvement of H4(D10S170) protein in ATM-dependent response to DNA damage (2007) (50)
Pax8 has a critical role in epithelial cell survival and proliferation (2013) (50)
The Adenovirus E1A gene blocks the differentiation of a thyroid epithelial cell line, however the neoplastic phenotype is achieved only after cooperation with other oncogenes. (1993) (50)
Activator protein-2 overexpression accounts for increased insulin receptor expression in human breast cancer. (2006) (49)
Cooperation between the polyomavirus middle-T-antigen gene and the human c-myc oncogene in a rat thyroid epithelial differentiated cell line: model of in vitro progression (1988) (49)
High-mobility group A2 gene expression is frequently induced in non-functioning pituitary adenomas (NFPAs), even in the absence of chromosome 12 polysomy. (2005) (49)
ONYX-015 enhances radiation-induced death of human anaplastic thyroid carcinoma cells. (2003) (49)
Autocrine stimulation by osteopontin plays a pivotal role in the expression of the mitogenic and invasive phenotype of RET/PTC-transformed thyroid cells (2004) (49)
CBX7 is a tumor suppressor in mice and humans (2012) (49)
New somatic mutations and WNK1-B4GALNT3 gene fusion in papillary thyroid carcinoma (2015) (49)
Critical Role of the HMGA2 Gene in Pituitary Adenomas (2006) (49)
miR-142-3p down-regulation contributes to thyroid follicular tumorigenesis by targeting ASH1L and MLL1. (2015) (49)
High-mobility group A1 proteins are overexpressed in human leukaemias. (2003) (48)
PATZ1 interacts with p53 and regulates expression of p53-target genes enhancing apoptosis or cell survival based on the cellular context (2013) (48)
NCOA4 transcriptional coactivator inhibits activation of DNA replication origins. (2014) (48)
[The activation of the phosphotyrosine phosphatase eta is responsible for the somatostatin inhibition of PCCl3 thyroid cell proliferation]. (2001) (48)
The cAMP-HMGA1-RBP4 system: a novel biochemical pathway for modulating glucose homeostasis (2009) (48)
Identification of the Genes Up- and Down-Regulated by the High Mobility Group A1 (HMGA1) Proteins (2004) (48)
Establishment of a non‐tumorigenic papillary thyroid cell line (FB‐2) carrying the RET/PTC1 rearrangement (2002) (46)
Expression and alternative splicing of c-ret RNA in papillary thyroid carcinomas (2001) (46)
Low frequency of p53 mutations in human thyroid tumours; p53 and Ras mutation in two out of fifty-six thyroid tumours. (1996) (46)
UbcH10 expression in human lymphomas (2009) (45)
The receptor-type protein tyrosine phosphatase J antagonizes the biochemical and biological effects of RET-derived oncoproteins. (2006) (45)
RET/PTC1 oncogene signaling in PC Cl 3 thyroid cells requires the small GTP-binding protein Rho (2001) (44)
Mitogenic effects of the up-regulation of minichromosome maintenance proteins in anaplastic thyroid carcinoma. (2005) (44)
The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma. (2004) (44)
Functional variants of the HMGA1 gene and type 2 diabetes mellitus. (2011) (44)
Cytokine production by a new undifferentiated human thyroid carcinoma cell line, FB-1. (1997) (44)
Translational regulation of a novel testis‐specific RNF4 transcript (2003) (43)
Thyrotropin receptor gene expression in oncogene-transfected rat thyroid cells: correlation between transformation, loss of thyrotropin-dependent growth, and loss of thyrotropin receptor gene expression. (1990) (43)
Down‐regulation of oestrogen receptor‐β associates with transcriptional co‐regulator PATZ1 delocalization in human testicular seminomas (2010) (43)
Lovastatin enhances the replication of the oncolytic adenovirus dl1520 and its antineoplastic activity against anaplastic thyroid carcinoma cells. (2007) (43)
In ataxia‐teleangiectasia betamethasone response is inversely correlated to cerebellar atrophy and directly to antioxidative capacity (2009) (43)
High mobility group A1 protein modulates autophagy in cancer cells (2017) (42)
PATZ1 acts as a tumor suppressor in thyroid cancer via targeting p53-dependent genes involved in EMT and cell migration (2015) (42)
The high‐mobility group A1‐estrogen receptor β nuclear interaction is impaired in human testicular seminomas (2012) (42)
A potential pathogenetic mechanism for multiple endocrine neoplasia type 2 syndromes involves ret-induced impairment of terminal differentiation of neuroepithelial cells. (1996) (42)
TWIST1 plays a pleiotropic role in determining the anaplastic thyroid cancer phenotype. (2011) (42)
Overexpression of proteins HMGA1 induces cell cycle deregulation and apoptosis in normal rat thyroid cells. (2018) (42)
Tumor suppressor role of the CL2/DRO1/CCDC80 gene in thyroid carcinogenesis. (2013) (42)
The insulin receptor: a new anticancer target for peroxisome proliferator-activated receptor-gamma (PPARgamma) and thiazolidinedione-PPARgamma agonists. (2008) (41)
H-Prune through GSK-3β interaction sustains canonical WNT/β-catenin signaling enhancing cancer progression in NSCLC (2014) (40)
High HMGA2 Expression and High Body Mass Index Negatively Affect the Prognosis of Patients With Ovarian Cancer (2013) (40)
PIT1 upregulation by HMGA proteins has a role in pituitary tumorigenesis. (2012) (40)
SOM230, A New Somatostatin Analogue, Is Highly Effective in the Therapy of Growth Hormone/Prolactin-Secreting Pituitary Adenomas (2007) (39)
PATZ Attenuates the RNF4-mediated Enhancement of Androgen Receptor-dependent Transcription* (2002) (39)
Molecular mechanisms of RET activation in human neoplasia (1999) (39)
A mos oncogene-containing retrovirus, myeloproliferative sarcoma virus, transforms rat thyroid epithelial cells and irreversibly blocks their differentiation pattern (1985) (39)
The HMGA1-IGF-I/IGFBP system: a novel pathway for modulating glucose uptake. (2012) (39)
Refined localization to contiguous regions on chromosome 10q of the two genes (H4 and RET) that form the oncogenic sequence PTC. (1991) (39)
Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease. (1998) (39)
Group I p21-activated kinases regulate thyroid cancer cell migration and are overexpressed and activated in thyroid cancer invasion. (2010) (39)
HMGA1-pseudogene overexpression contributes to cancer progression (2014) (38)
Transformation of rat thyroid epithelial cells by kirsten murine sarcoma virus (1981) (38)
20 years of RET/PTC in thyroid cancer: clinico-pathological correlations. (2007) (38)
A new mechanism of BRAF activation in human thyroid papillary carcinomas. (2005) (38)
Overexpression of the S-phase kinase-associated protein 2 in thyroid cancer. (2007) (38)
Suppression of HMGA2 protein synthesis could be a tool for the therapy of well differentiated liposarcomas overexpressing HMGA2. (2018) (37)
CDH16/Ksp-cadherin is expressed in the developing thyroid gland and is strongly down-regulated in thyroid carcinomas. (2012) (37)
The High Mobility Group A proteins contribute to thyroid cell transformation by regulating miR‐603 and miR‐10b expression (2013) (36)
High mobility group A1 protein expression reduces the sensitivity of colon and thyroid cancer cells to antineoplastic drugs (2014) (36)
Human N-ras, TRK-T1, and RET/PTC3 oncogenes, driven by a thyroglobulin promoter, differently affect the expression of differentiation markers and the proliferation of thyroid epithelial cells. (1999) (36)
The Kirsten murine sarcoma virus induces rat thyroid carcinomas in vivo. (1989) (35)
Deregulation of miR-183 and KIAA0101 in Aggressive and Malignant Pituitary Tumors (2015) (35)
CCDC6 represses CREB1 activity by recruiting histone deacetylase 1 and protein phosphatase 1 (2010) (35)
Akt/protein kinase B promotes survival and hormone-independent proliferation of thyroid cells in the absence of dedifferentiating and transforming effects. (2000) (35)
Loss of CCDC6, the First Identified RET Partner Gene, Affects pH2AX S139 Levels and Accelerates Mitotic Entry upon DNA Damage (2012) (35)
HMGA1-pseudogenes and cancer (2016) (34)
Diagnostic Significance of High Mobility Group I(Y) Protein Expression in Intraductal Papillary Mucinous Tumors of the Pancreas (2002) (33)
Tumor suppressor activity of CBX7 in lung carcinogenesis (2012) (33)
Expression of the RET oncogene induces differentiation of SK-N-BE neuroblastoma cells. (1995) (33)
HMGA1 protein expression sensitizes cells to cisplatin-induced cell death (2005) (33)
HMGA1P7-pseudogene regulates H19 and Igf2 expression by a competitive endogenous RNA mechanism (2016) (33)
A truncated HMGA1 gene induces proliferation of the 3T3-L1 pre-adipocytic cells: a model of human lipomas. (2003) (33)
The Phosphotyrosine Phosphatase η Mediates Somatostatin Inhibition of Glioma Proliferation via the Dephosphorylation of ERK1/2 (2004) (33)
UBE2C Is a Transcriptional Target of the Cell Cycle Regulator FOXM1 (2018) (32)
Identification and characterization of a novel RING-finger gene (RNF4) mapping at 4p16.3. (1998) (32)
Role of the high mobility group A proteins in the regulation of pituitary cell cycle. (2010) (32)
The impairment of the High Mobility Group A (HMGA) protein function contributes to the anticancer activity of trabectedin. (2013) (32)
An intracellular multi-effector complex mediates somatostatin receptor 1 activation of phospho-tyrosine phosphatase eta. (2007) (32)
Embryonic defects and growth alteration in mice with homozygous disruption of the Patz1 gene (2013) (32)
HMGA1 silencing reduces stemness and temozolomide resistance in glioblastoma stem cells (2016) (32)
A polymorphism of HMGA1 protects against proliferative diabetic retinopathy by impairing HMGA1-induced VEGFA expression (2016) (32)
Rat protein tyrosine phosphatase η physically interacts with the PDZ domains of syntenin (2001) (32)
HMGA1 Expression in Human Hepatocellular Carcinoma Correlates with Poor Prognosis and Promotes Tumor Growth and Migration in in vitro Models1 (2016) (31)
The activation of the phosphotyrosine phosphatase eta (r-PTP eta) is responsible for the somatostatin inhibition of PC Cl3 thyroid cell proliferation. (2001) (31)
Isolation and functional characterization of peptide agonists of PTPRJ, a tyrosine phosphatase receptor endowed with tumor suppressor activity. (2012) (31)
High-mobility group A1 protein inhibits p53-mediated intrinsic apoptosis by interacting with Bcl-2 at mitochondria (2012) (30)
Neoplastic transformation inactivates specific trans-acting factor(s) required for the expression of the thyroglobulin gene. (1988) (30)
A TSH-CREB1-microRNA loop is required for thyroid cell growth. (2011) (30)
High mobility group HMGI(Y) protein expression in human colorectal hyperplastic and neoplastic diseases. (2001) (30)
Regulation of microRNA expression by HMGA1 proteins (2009) (30)
HMGA2 locus rearrangement in a case of acute lymphoblastic leukemia. (2003) (29)
Let-7a down-regulation plays a role in thyroid neoplasias of follicular histotype affecting cell adhesion and migration through its ability to target the FXYD5 (Dysadherin) gene. (2012) (29)
The Long Non-Coding RNA Prader Willi/Angelman Region RNA5 (PAR5) Is Downregulated in Anaplastic Thyroid Carcinomas Where It Acts as a Tumor Suppressor by Reducing EZH2 Activity (2020) (29)
Protein tyrosine phosphatase PTPRJ is negatively regulated by microRNA‐328 (2013) (29)
Loss of p27 Expression Through RAS->BRAF->MAP Kinase-Dependent Pathway in Human Thyroid Carcinomas (2007) (29)
Development of mammary and cutaneous gland tumors in transgenic mice carrying the RET/PTC1 oncogene. (1996) (29)
A new T helper 17 cytokine in hidradenitis suppurativa: antimicrobial and proinflammatory role of interleukin‐26 (2019) (29)
Epigenetic Mechanisms Leading to Overexpression of HMGA Proteins in Human Pituitary Adenomas (2015) (29)
Critical role of CCDC6 in the neoplastic growth of testicular germ cell tumors (2013) (29)
Discovery of PTPRJ agonist peptides that effectively inhibit in vitro cancer cell proliferation and tube formation. (2013) (28)
Activated RET/PTC oncogene elicits immediate early and delayed response genes in PC12 cells. (1995) (28)
High mobility group A1 expression correlates with the histological grade of human glial tumors. (2004) (28)
Thyrotropin regulates thyroid cell proliferation by up-regulating miR-23b and miR-29b that target SMAD3. (2012) (28)
Role of PTPRJ genotype in papillary thyroid carcinoma risk. (2010) (28)
Status and expression of the p16INK4 gene in human thyroid tumors and thyroid‐tumor cell lines (1996) (28)
High mobility group A1 is expressed in metastatic adenocarcinoma to the liver and intrahepatic cholangiocarcinoma, but not in hepatocellular carcinoma: its potential use in the diagnosis of liver neoplasms (2003) (28)
A KRAB zinc finger protein gene is the potential target of 19q13 translocation in benign thyroid tumors (1999) (27)
Therapy of human pancreatic carcinoma based on suppression of HMGA1 protein synthesis in preclinical models (2004) (27)
Thymosin beta-10 gene overexpression correlated with the highly malignant neoplastic phenotype of transformed thyroid cells in vivo and in vitro. (1998) (27)
Fenofibrate increases the expression of high mobility group AT-hook 2 (HMGA2) gene and induces adipocyte differentiation of orbital fibroblasts from Graves' ophthalmopathy. (2004) (27)
UbcH10 overexpression in human lung carcinomas and its correlation with EGFR and p53 mutational status. (2013) (27)
UBE2C is overexpressed in ESCC tissues and its abrogation attenuates the malignant phenotype of ESCC cell lines (2016) (27)
Tyrosine Phosphatase PTPRJ/DEP-1 Is an Essential Promoter of Vascular Permeability, Angiogenesis, and Tumor Progression. (2016) (27)
CBX7 Modulates the Expression of Genes Critical for Cancer Progression (2014) (27)
HIPK2 deficiency causes chromosomal instability by cytokinesis failure and increases tumorigenicity (2015) (26)
E2F1 activation is responsible for pituitary adenomas induced by HMGA2 gene overexpression (2006) (26)
HMGA2 overexpression plays a critical role in the progression of esophageal squamous carcinoma (2016) (26)
HMGA Proteins Upregulate CCNB 2 Gene in Mouse and Human Pituitary Adenomas (2009) (26)
Point mutation in GRIM-19: a new genetic lesion in Hurthle cell thyroid carcinomas (2005) (25)
Analysis of UbcH10 expression represents a useful tool for the diagnosis and therapy of astrocytic tumors. (2008) (25)
Cloning of the rat tissue inhibitor of metalloproteinases type 2 (TIMP-2) gene: analysis of its expression in normal and transformed thyroid cells. (1994) (25)
Complementary actions of dopamine D2 receptor agonist and anti‐vegf therapy on tumoral vessel normalization in a transgenic mouse model (2017) (24)
Oncogene transformation of PC Cl3 clonal thyroid cell line induces an autonomous pattern of proliferation that correlates with a loss of basal and stimulated phosphotyrosine phosphatase activity. (1997) (24)
HMGA1 protein is a novel target of the ATM kinase. (2008) (24)
Derepression of HMGA2 Gene Expression in Retinoblastoma Is Associated with Cell Proliferation (2003) (24)
Overexpression of the HIP gene coding for a heparin/heparan sulfate-binding protein in human thyroid carcinomas. (1998) (24)
HMGA1 protein expression in familial breast carcinoma patients. (2010) (23)
Genetic ablation of homeodomain-interacting protein kinase 2 selectively induces apoptosis of cerebellar Purkinje cells during adulthood and generates an ataxic-like phenotype (2015) (23)
A 12q13 translocation involving the HMGI-C gene in richter transformation of a chronic lymphocytic leukemia. (2000) (23)
UbcH10 expression can predict prognosis and sensitivity to the antineoplastic treatment for colorectal cancer patients (2016) (23)
The HMGA1 Pseudogene 7 Induces miR-483 and miR-675 Upregulation by Activating Egr1 through a ceRNA Mechanism (2017) (23)
The rat tyrosine phosphatase η increases cell adhesion by activating c-Src through dephosphorylation of its inhibitory phosphotyrosine residue (2005) (23)
CBX7 and HMGA1b proteins act in opposite way on the regulation of the SPP1 gene expression (2015) (23)
Critical role of cyclin D3 in TSH-dependent growth of thyrocytes and in hyperproliferative diseases of the thyroid gland (2003) (23)
Continuous suppression of globin gene expression and differentiation of Friend erythroleukemia cells by phorbol 12-myristate 13-acetate (PMA) despite the loss of PMA binding sites by down regulation. (1984) (22)
A ceRNA circuitry involving the long noncoding RNA Klhl14-AS, Pax8 and Bcl2 drives thyroid carcinogenesis. (2019) (22)
Presence of physiologically stimulated RET in adult rat brain: induction of RET expression during nerve regeneration. (1996) (22)
from patients with acute myeloid leukemias 5-Aza-2'-deoxycytidine induces terminal differentiation of leukemic blasts (2011) (22)
Restoration of CBX7 expression increases the susceptibility of human lung carcinoma cells to irinotecan treatment (2015) (22)
Hmga2 is necessary for Otx2-dependent exit of embryonic stem cells from the pluripotent ground state (2016) (22)
A differential proteomic approach to identify proteins associated with thyroid cell transformation. (2005) (22)
Isolation of a SIR-like gene, SIR-T8, that is overexpressed in thyroid carcinoma cell lines and tissues (2002) (22)
miR-155 is positively regulated by CBX7 in mouse embryonic fibroblasts and colon carcinomas, and targets the KRAS oncogene (2017) (21)
Interaction between HMGA1 and Retinoblastoma Protein Is Required for Adipocyte Differentiation* (2009) (21)
HMGA1 negatively regulates NUMB expression at transcriptional and post transcriptional level in glioblastoma stem cells (2019) (21)
The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. (2016) (21)
Targeted disruption of the murine homeodomain-interacting protein kinase-2 causes growth deficiency in vivo and cell cycle arrest in vitro. (2009) (20)
Overexpression of HMGA1 Figures as a Potential Prognostic Factor in Endometrioid Endometrial Carcinoma (EEC) (2019) (20)
Thymosin beta-10 gene expression as a possible tool in diagnosis of thyroid neoplasias. (2004) (20)
Ccdc6 knock-in mice develop thyroid hyperplasia associated to an enhanced CREB1 activity (2015) (20)
Deregulation of HMGA1 expression induces chromosome instability through regulation of spindle assembly checkpoint genes (2015) (20)
Thymosin beta-10 protein synthesis suppression reduces the growth of human thyroid carcinoma cells in semisolid medium. (2002) (20)
Betamethasone therapy in ataxia telangiectasia: unraveling the rationale of this serendipitous observation on the basis of the pathogenesis (2013) (20)
Wnt4 inhibits cell motility induced by oncogenic Ras (2013) (20)
Novel mutation of the PTEN gene in an Italian Cowden's disease kindred. (1998) (19)
Glial cell line-derived neurotrophic factor induces proliferative inhibition of NT2/D1 cells through RET-mediated up-regulation of the cyclin-dependent kinase inhibitor p27kip 1 (2002) (19)
Sp1 and CTF/NF-1 transcription factors are involved in the basal expression of the Hmgi-c proximal promoter. (1999) (19)
Molecular Cloning of PTC, a New Oncogene Found Activated in Human Thyroid Papillary Carcinomas and Their Lymph Node Metastases a (1988) (19)
UbcH10 expression on thyroid fine‐needle aspirates (2010) (19)
HMGA2, but not HMGA1, is overexpressed in human larynx carcinomas (2018) (19)
Aberrant expression, function and localization of connexins in human esophageal carcinoma cell lines with different degrees of tumorigenicity (2005) (19)
Potentiation of the malignant phenotype of the undifferentiated ARO thyroid cell line by insertion of the bcl‐2 gene (1999) (18)
Expression of the soluble lectin L-14 gene is induced by TSH in thyroid cells and suppressed by retinoic acid in transformed neural cells. (1994) (18)
Detection of high mobility group A2 specific mRNA in the plasma of patients affected by epithelial ovarian cancer (2015) (18)
DNA methylation state of the galectin-3 gene represents a potential new marker of thyroid malignancy (2013) (18)
Erratum: The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells (American Society for Clinical Investigation (2005) 115:4 (1068-1081) DOI: 10.1172/JCI22758) (2016) (18)
FEZ1/LZTS1 protein expression in ovarian cancer (2010) (18)
The R3 receptor-like protein tyrosine phosphatase subfamily inhibits insulin signalling by dephosphorylating the insulin receptor at specific sites. (2015) (18)
Regulation of microRNA expression by HMGA1 proteins (2016) (18)
High intrafamilial variability in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy: A case study (2011) (18)
Oncogenic Properties of the Antisense lncRNA COMET in BRAF- and RET-Driven Papillary Thyroid Carcinomas. (2019) (17)
Identification of a novel subtype of H4-RET rearrangement in a thyroid papillary carcinoma and lymph node metastasis. (2000) (17)
Critical role of HMGA proteins in cancer cell chemoresistance (2017) (17)
Identification of Sumoylation Sites in CCDC6, the First Identified RET Partner Gene in Papillary Thyroid Carcinoma, Uncovers a Mode of Regulating CCDC6 Function on CREB1 Transcriptional Activity (2012) (17)
HMGA and Cancer: A Review on Patent Literatures. (2019) (17)
Low-resolution structure and fluorescence anisotropy analysis of protein tyrosine phosphatase eta catalytic domain. (2007) (17)
The receptor protein tyrosine phosphatase PTPRJ negatively modulates the CD98hc oncoprotein in lung cancer cells (2018) (17)
Mycalol: a natural lipid with promising cytotoxic properties against human anaplastic thyroid carcinoma cells. (2013) (17)
HAND1 gene expression is negatively regulated by the High Mobility Group A1 proteins and is drastically reduced in human thyroid carcinomas (2009) (17)
Protein tyrosine phosphatase-eta expression is upregulated by the PKA-dependent and is downregulated by the PKC-dependent pathways in thyroid cells. (1998) (16)
Impairment of the p27kip1 function enhances thyroid carcinogenesis in TRK-T1 transgenic mice. (2009) (16)
HMGA1-Regulating microRNAs Let-7a and miR-26a are Downregulated in Human Seminomas (2020) (16)
Retraction: Identification of new high mobility group A1 associated proteins (2007) (16)
The eighth fibronectin type III domain of protein tyrosine phosphatase receptor J influences the formation of protein complexes and cell localization. (2009) (16)
Different mutations of the RET gene cause different human tumoral diseases. (1999) (16)
High mobility group A1 enhances tumorigenicity of human cholangiocarcinoma and confers resistance to therapy (2017) (16)
CBX7 gene expression plays a negative role in adipocyte cell growth and differentiation (2014) (16)
Ligand Stimulation of a Ret Chimeric Receptor Carrying the Activating Mutation Responsible for the Multiple Endocrine Neoplasia Type 2B* (1996) (15)
Protein kinase C activities are increased in rat thyroid epithelial cells expressing v-ras genes. (1988) (15)
Involvement of the HMGI(Y) gene in a microfollicular adenoma of the thyroid (1999) (15)
Only the substitution of methionine 918 with a threonine and not with other residues activates RET transforming potential. (1997) (15)
The cl2/dro1/ccdc80 null mice develop thyroid and ovarian neoplasias. (2015) (15)
The complex CBX7-PRMT1 has a critical role in regulating E-cadherin gene expression and cell migration. (2019) (15)
The block of thyroglobulin synthesis, which occurs upon transformation of rat thyroid epithelial cells, is at the transcriptional level and it is associated with methylation of the 5' flanking region of the gene. (1989) (14)
HMGA1 overexpression is associated with a particular subset of human breast carcinomas (2015) (14)
B-RAF mutations are a rare event in pituitary adenomas (2007) (14)
High-mobility-group A1 (HMGA1) proteins down-regulate the expression of the recombination activating gene 2 (RAG2). (2005) (14)
POZ-, AT-hook-, and Zinc Finger-containing Protein (PATZ) Interacts with Human Oncogene B Cell Lymphoma 6 (BCL6) and Is Required for Its Negative Autoregulation* (2012) (14)
The Mia/Cd-rap gene expression is downregulated by the high-mobility group A proteins in mouse pituitary adenomas. (2007) (13)
A 3.4-kbp transcript of ZNF331 is solely expressed in follicular thyroid adenomas (2003) (13)
Possible role of activated ras genes in human esophageal carcinogenesis (1993) (13)
Differential HMGA expression and post-translational modifications in prostatic tumor cells. (2005) (13)
The Kinase Inhibitor PP 1 Blocks Tumorigenesis Induced by RET Oncogenes 1 (2002) (13)
RPSAP52 lncRNA inhibits p21Waf1/CIP expression by interacting with the RNA binding protein HuR. (2019) (13)
Identification of HMGA2 inhibitors by AlphaScreen-based ultra-high-throughput screening assays (2020) (13)
HMGA 1 Protein Overexpression in Human Breast Carcinomas : Correlation with ErbB 2 Expression (2004) (13)
The highly malignant phenotype of anaplastic thyroid carcinoma cell lines is recessive. (2000) (12)
UBE 2 C Is a Transcriptional Target of the Cell Cycle Regulator FOXM 1 (2018) (12)
The Long Non-Coding RNA RP5-1024C24.1 and Its Associated-Gene MPPED2 Are Down-Regulated in Human Thyroid Neoplasias and Act as Tumour Suppressors (2018) (12)
Role of Dicer1 in thyroid cell proliferation and differentiation (2017) (12)
High-Mobility Group A1 Protein: A New Coregulator of Peroxisome Proliferator–Activated Receptor-&ggr;–Mediated Transrepression in the Vasculature (2012) (12)
PATZ1 is a target of miR-29b that is induced by Ha-Ras oncogene in rat thyroid cells (2016) (12)
The “next-generation” knowledge of papillary thyroid carcinoma (2015) (11)
Alpha 1A- and alpha 1B-adrenergic receptors mediate the effect of norepinephrine on cytosolic calcium levels in rat PC C13 thyroid cells: thyrotropin modulation of alpha 1B-linked response via a adenosine 3',5'-monophosphate-protein kinase-A-dependent pathway. (1994) (11)
miR-130b-3p Upregulation Contributes to the Development of Thyroid Adenomas Targeting CCDC6 Gene (2015) (11)
Mitogenic and dedifferentiating effect of the K-fgf/hst oncogene on rat thyroid PC clone 3 epithelial cells. (1993) (11)
IFN-γ gene expression is controlled by the architectural transcription factor HMGA1 (2005) (11)
Pivotal role of the RB family proteins in in vitro thyroid cell transformation. (2000) (11)
The rat tyrosine phosphatase η increases cell adhesion by activating c-Src through dephosphorylation of its inhibitory phosphotyrosine residue (2005) (11)
Expression of CD133 in differentiated thyroid cancer of young patients (2015) (11)
Hmga1 null mouse embryonic fibroblasts display downregulation of spindle assembly checkpoint gene expression associated to nuclear and karyotypic abnormalities (2016) (10)
Characterization of inflammatory infiltrate of ulcerative dermatitis in C57BL/6NCrl-Tg(HMGA1P6)1Pg mice (2018) (10)
High Mobility Group A proteins in esophageal carcinomas (2016) (10)
Activated RET oncogene products induce maturation of xenopus oocytes. (1995) (10)
p53 genes mutated in the DNA binding site or at a specific COOH-terminal site exert divergent effects on thyroid cell growth and differentiation. (1998) (10)
HMGI-C gene expression is not required for in vivo thyroid cell transformation. (2001) (10)
Somatostatin Inhibits PC Cl3 Thyroid Cell Proliferation through the Modulation of Phosphotyrosine Phosphatase Activity (1996) (10)
Comprehensive conventional and molecular cytogenetic characterization of B-CPAP, a human papillary thyroid carcinoma-derived cell line. (2004) (10)
Regulation of thymosin beta10 expression by TSH and other mitogenic signals in the thyroid gland and in cultured thyrocytes. (1999) (10)
Breakpoints of 19q13 translocations of benign thyroid tumors map within a 400 kilobase region (1997) (9)
The ret protooncogene is expressed in normal human parafollicular thyroid-cells. (1994) (9)
HMGA2 cooperates with either p27kip1 deficiency or Cdk4R24C mutation in pituitary tumorigenesis (2018) (9)
The v-erbA oncogene selectively inhibits iodide uptake in rat thyroid cells. (1996) (9)
Glial cell line-derived neurotrophic factor induces proliferative inhibition of NT2/D1 cells through RET-mediated up-regulation of the cyclin-dependent kinase inhibitor p27(kip1). (2002) (9)
Molecular mechanisms of the increased glucose transport in transformed FRTL-5 rat thyroid cells. (1993) (8)
Homeodomain-interacting Protein Kinase-2 Stabilizes p27kip1 by Its Phosphorylation at Serine 10 and Contributes to Cell Motility* (2011) (8)
Interplay between HMGA and TP53 in cell cycle control along tumor progression (2020) (8)
The Metallophosphoesterase-Domain-Containing Protein 2 (MPPED2) Gene Acts as Tumor Suppressor in Breast Cancer (2019) (8)
Regulation of p 27 Kip 1 Protein Levels Contributes to Mitogenic Effects of the RET / PTC Kinase in Thyroid Carcinoma Cells (2004) (8)
TPA induces a block of differentiation and increases the susceptibility to neoplastic transformation of a rat thyroid epithelial cell line. (1998) (7)
Hmga1 null mice are less susceptible to chemically induced skin carcinogenesis. (2008) (7)
IFN-gamma gene expression is controlled by the architectural transcription factor HMGA1. (2005) (7)
Expression, purification, and characterization of rat protein tyrosine phosphatase η catalytic domain (2005) (7)
New drugs in thyroid cancer. (2007) (7)
TACC3 mediates the association of MBD2 with histone acetyltransferases and relieves transcriptional repression of methylated promoters (2006) (7)
Ionizing Radiation Deregulates the MicroRNA Expression Profile in Differentiated Thyroid Cells. (2018) (7)
Oncogenic protein tyrosine kinases (2004) (7)
HMGA1-pseudogene7 transgenic mice develop B cell lymphomas (2020) (7)
Loss of One or Two PATZ1 Alleles Has a Critical Role in the Progression of Thyroid Carcinomas Induced by the RET/PTC1 Oncogene (2018) (7)
Structural Model of the hUbA1-UbcH10 Quaternary Complex: In Silico and Experimental Analysis of the Protein-Protein Interactions between E1, E2 and Ubiquitin (2014) (7)
Transcriptional Profile of Ki-Ras-Induced Transformation of Thyroid Cells (2007) (6)
Aza-2 ’-Deoxycytidine Induces Terminal Differentiation of Leukemic Blasts From Patients With Acute Myeloid Leukemias (2005) (6)
Anti-VEGF therapy in breast and lung mouse models of cancers. (2011) (6)
High-mobility group A 1 inhibits p 53 by cytoplasmic relocalization of its proapoptotic activator HIPK 2 (2018) (6)
Emerging Role of USP8, HMGA, and Non-Coding RNAs in Pituitary Tumorigenesis (2019) (6)
ONYX-015 , an E 1 B Gene-Defective Adenovirus , Induces Cell Death in Human Anaplastic Thyroid Carcinoma Cell Lines (2002) (6)
HAND1 gene expression is negatively regulated by the High Mobility Group A1 proteins and is drastically reduced in human thyroid carcinomas (2009) (6)
[Description of cell line established from human thyroid papillary cancer and secreting human chorionic gonadotropin hormone]. (1992) (6)
CBX7 Expression in Oncocytic Thyroid Neoplastic Lesions (Hürthle Cell Adenomas and Carcinomas) (2014) (6)
POZ-, AT-hook-, and zinc finger-containing protein (PATZ) interacts with human oncogene B cell lymphoma 6 (BCL6) and is required for its negative autoregulation. (2014) (6)
A novel splice variant of the protein tyrosine phosphatase PTPRJ that encodes for a soluble protein involved in angiogenesis (2016) (6)
CaV 2 . 3 channel and PKC λ : new players in insulin secretion (2004) (6)
Expression of a truncated Hmga1b gene induces gigantism, lipomatosis and B-cell lymphomas in mice. (2011) (6)
Overexpression of Proteins HMGA 1 Induces Cell Cycle Deregulation and Apoptosis in Normal Rat Thyroid Cells 1 (2001) (5)
MicroRNAs: a great challenge for the diagnosis and therapy of endocrine cancers. (2010) (5)
Deregulation of microRNA expression in human thyroid carcinomas (2010) (5)
Up-regulation of miR-146b and down-regulation of miR-200b contribute to the cytotoxic effect of histone deacetylase inhibitors on ras-transformed thyroid cells. (2013) (5)
Human papilloma virus 16 E7 oncogene does not cooperate with RET/PTC 3 oncogene in the neoplastic transformation of thyroid cells in transgenic mice. (2001) (5)
Impairment of the p 27 kip 1 function enhances thyroid carcinogenesis in TRK-T 1 transgenic mice (2009) (5)
Inhibitory effects of 2-iodohexadecanal on FRTL-5 thyroid cells proliferation (2015) (5)
Double knock-out of Hmga1 and Hipk2 genes causes perinatal death associated to respiratory distress and thyroid abnormalities in mice (2019) (5)
High mobility group A-interacting proteins in cancer: focus on chromobox protein homolog 7, homeodomain interacting protein kinase 2 and PATZ (2012) (5)
Expression of the onc gene of the Kirsten murine sarcoma virus in differentiated rat thyroid epithelial cell lines. (1984) (5)
Critical role of the high mobility group A proteins in hematological malignancies (2021) (5)
Homeodomain-interacting protein kinase-2 stabilizes p27kip1 by its phosphorylation at serine 10 and contributes to cell motility (2014) (5)
Intrinsic LINE-1 Hypomethylation and Decreased Brca1 Expression are Associated with DNA Repair Delay in Irradiated Thyroid Cells (2017) (5)
A retrovirus carrying the polyomavirus middle T gene induces acute thrombocythemic myeloproliferative disease in mice (1988) (5)
Correction: DNA Damage, Homology-Directed Repair, and DNA Methylation (2017) (4)
Identification and Synthesis of Mycalol Analogues with Improved Potency against Anaplastic Thyroid Carcinoma Cell Lines. (2017) (4)
HMGA1 induces EZH2 overexpression in human B-cell lymphomas. (2021) (4)
Norepinephrine and thyrotropin stimulation of [Ca++]i in PC C13 a rat thyroid epithelial cell line: effect of transformation by E1A gene adenovirus and polyomavirus middle-T antigen gene. (1993) (4)
The relationship of modulation of major histocompatibility complex class I antigens to retrovirus transformation in rat cell lines. (1988) (4)
The High Mobility Group A 2 Gene Is Amplified and Overexpressed in Human Prolactinomas 1 (2002) (4)
siRNA nanoformulation against the Ret/PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinoma (2007) (4)
Setting up and exploitation of a nano/technological platform for the evaluation of HMGA1b protein in peripheral blood of cancer patients. (2019) (4)
Characterization of HMGA1P6 transgenic mouse embryonic fibroblasts (2020) (4)
Characterization of 2 novel and 2 recurring BRCA1 germline mutations in breast and/or ovarian carcinoma patients from the area of Naples. (2002) (3)
High-mobility-group A 1 ( HMGA 1 ) proteins downregulate the expression of the recombination activating gene 2 ( RAG 2 ) (2005) (3)
Association between the expression of E1A oncogene and increased sensitivity to growth inhibition induced by sustained levels of cAMP in rat thyroid cells. (2000) (3)
Attenuates the RNF 4-mediated Enhancement of Androgen Receptor-dependent Transcription * (2002) (3)
Radiation-induced senescence and thyroid cancer: a barrier or a driving force (2015) (3)
The HMGA1-pseudogene7 shows oncogenic activity in vivo (2020) (3)
UbcH10 overexpression is less pronounced in older colorectal cancer patients (2016) (3)
Retraction: HMGA Proteins Up-regulate CCNB2 Gene in Mouse and Human Pituitary Adenomas. (2018) (3)
Ret-mediated Mitogenesis Requires Src Kinase Activity 1 (1999) (3)
Expression, purification, and characterization of rat protein tyrosine phosphatase eta catalytic domain. (2005) (2)
2-iodohexadecanal Inhibits thyroid cell growth in part through the induction of let-7f microRNA (2015) (2)
One-andTwo-Step Transformations ofRatThyroid Epithelial Cells byRetroviral Oncogenes (1987) (2)
411 A new T helper 17 cytokine in hidradenitis suppurativa: antimicrobial and pro-inflammatory role of IL-26 (2019) (2)
Histone and nonhistone proteins from normal and virus-transformed rat thyroid epithelial cells. (1987) (2)
In vitro transformation of epithelial cell by acute retroviruses. (1986) (2)
CBX 7 gene expression plays a negative role in adipocyte cell growth and differentiation (2014) (2)
Association between the expression of E 1 A oncogene and increased sensitivity to growth inhibition induced by sustained levels of cAMP in rat thyroid cells (2000) (2)
Production of tgf-Beta and hgf receptor by a differentiated papillary thyroid-carcinoma cell-line (B-cpap) - implication in malignancy. (1995) (2)
Hmga2 Cooperates with Either p27 Deficiency or Cdk4 R24C Mutation in Pituitary Tumourigenesis (2018) (2)
RFLP for TaqI of the human thyroid papillary carcinoma (PTC) oncogene. (1988) (2)
MPPED2 is downregulated in glioblastoma, and its restoration inhibits proliferation and increases the sensitivity to temozolomide of glioblastoma cells (2021) (1)
Suramin potently inhibits binding of the mammalian high mobility group protein AT-hook 2 to DNA (2019) (1)
Modulation of Thyroid Epithelial Differentiation by Two Viral Oncogenes (1984) (1)
thyroid carcinogenesis in TRK-T1 transgenic mice (2009) (1)
Endocannabinoids as emerging suppressors of angiogenesis and breast tumor growth and metastatic spreading ” (2008) (1)
The R156H variation in IL-12R beta 1 is not a mutation (2013) (1)
Control of breast cancer cell growth by adipocyte-released factors ” (2009) (1)
SymposiumRole of oncogene activation in human thyroid carcinomas (1990) (1)
Activation of the ret oncogene in human thyroid carcinomas (1993) (1)
Corrigendum to “HMGA1 expression in human hepatocellular carcinoma correlates with poor prognosis and promotes tumor growth and migration in in vitro models” [Neoplasia 18 (2016) 724–731]☆ (2020) (1)
Retraction to: High-mobility group A1 protein inhibits p53-mediated intrinsic apoptosis by interacting with Bcl-2 at mitochondria (2014) (1)
Retraction Note: High Mobility Group A1 (HMGA1) proteins interact with p53 and inhibit its apoptotic activity (2013) (1)
Noncoding RNAs in Thyroid-Follicular-Cell-Derived Carcinomas (2022) (1)
The role of HMGA1 protein in gastroenteropancreatic neuroendocrine tumors (2022) (1)
Docetaxel in adjuvant therapy of breast cancer : results of the TAXIT 216 multicenter phase III trial ” (2008) (1)
Crystallization and preliminary X-ray diffraction analysis of rat protein tyrosine phosphatase eta. (2006) (1)
HMGA1: A choice of symmetry (2014) (1)
Thyroid Neoplastic Transformation In Vitro and In Vivo (1984) (1)
Pituitary Adenoma: Role of HMGA Proteins (2013) (1)
Crystallization and preliminary X-ray diffraction analysis of rat protein tyrosine phosphatase η (2006) (1)
Identification of a Chimeric Gene Frequently Activated in Human Thyroid Papillary Carcinomas (1993) (1)
Intracellular Signaling by the ret Tyrosine Kinase (1996) (1)
High mobility group A1 protein expression reduces the sensitivity of colon and thyroid cancer cells to antineoplastic drugs (2014) (1)
Corrigendum to “The high mobility group A proteins contribute to thyroid cell transformation by regulating miR‐603 and miR‐10b expression” [Mol. Oncol. 7 (3) (Jan. 2013) 531–542] (2014) (1)
The PTC oncogene is able to dedifferentiate a rat thyroid epithelial cell line in culture (1992) (1)
Erratum: Isolation of a SIR-like gene, SIR-T8, that is overexpressed in thyroid carcinoma cell lines and tissues (British Journal of Cancer (2002) 86 (917-923)) (2002) (1)
Retraction for Berlingieri et al., “Inhibition of HMGI-C Protein Synthesis Suppresses Retrovirally Induced Neoplastic Transformation of Rat Thyroid Cells” (2018) (1)
Interaction between HMGA1 and retinoblastoma protein is required for adipocyte differentiation (2014) (1)
Genetic alterations in differentiated thyroid cancer: what can be expected for gene expression profiling of thyroid carcinomas. (2003) (1)
The ret protooncogene is expressed in predominantly epithelial human thymomas. (1994) (1)
Retraction notice to “Expression of a truncated Hmga1b gene induces gigantism, lipomatosis and B-cell lymphomas in mice” [Eur J Cancer 47 (2011) 470–478]. (2015) (1)
2 The Genetics of Pituitary Adenomas (2012) (1)
Retraction: INrf2 (Keap1) targets Bcl-2 degradation and controls cellular apoptosis (2014) (1)
POZ-, AT-hook-, and zinc finger-containing protein (PATZ) interacts with the human oncogene B cell lymphoma 6 (BCL6) and is required for its negative autoregulation. (2017) (0)
Correction to: Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas (2022) (0)
Retraction for Trapasso et al., “Rat Protein Tyrosine Phosphatase η Suppresses the Neoplastic Phenotype of Retrovirally Transformed Thyroid Cells through the Stabilization of p27Kip1” (2018) (0)
Effect of viral oncogenes transformation on TSH- and norepinephrine-evoked [Ca++]i increase in rat thyroid cells (1992) (0)
Glitazone-mediated vascular protection requires high mobility group A1 protein – a new PPARgamma coregulator (2010) (0)
Malignant Phenotype in Thyroid Cancer Gene Expression Correlates with a Highly CBX 7 Loss of the Updated (2008) (0)
Patologia. - Glial cell line-derived neurotrophic factor (GDNF) stimulates ret activity (1997) (0)
Gene expression profile analysis of pituitary adenomas developed by HMGA transgenic mice ” (2007) (0)
693 Tumour Suppressor Activity of Cbx7 in Lung Carcinogenesis (2012) (0)
Multiple Mechanisms ofInterference between Transformation andDifferentiation inThyroid Cells (1992) (0)
High Mobility Group A 1 ( HMGA 1 ) protein inhibits p 53-mediated intrinsic apoptosis interacting with Bcl-2 at mitochondria (2011) (0)
170 PATZ1 is a New Candidate Tumour-suppressor Gene in Thyroid Cancer (2012) (0)
Glial cell line-derived nenrotrophic factor (GDNF) stimulates ret activity (1997) (0)
Restoration of CBX7 expression increases the susceptibility of human lung carcinoma cells to irinotecan treatment (2015) (0)
161 CBX7 Exerts its Tumour-suppressive Function by Repressing the Expression of the SPP1 Gene (2012) (0)
Critical role of HMGA proteins in cancer cell chemoresistance (2017) (0)
Subject Index Vol. 4, 2015 (2015) (0)
Abstract 8: The protein tyrosine phosphatase DEP-1/PTPRJ is an essential promoter of vascular permeability, angiogenesis and tumor progression (2014) (0)
Molecular mechanisms of thyroid carcinogenesis: role of the CBX7 gene: Loss of the CBX7 gene.ll (2008) (0)
in Crohn's Disease Bioactive IL-18 Expression Is Up-Regulated (1999) (0)
Retraction for Fusco et al., “One- and Two-Step Transformations of Rat Thyroid Epithelial Cells by Retroviral Oncogenes” (2018) (0)
UBE 2 C ( ubiquitin-conjugating enzyme E 2 C ) (2011) (0)
185 Role of HMGA1 Pseudogenes in Human Cancer (2012) (0)
Growth and Differentiation COOH-terminal Site Exert Divergent Effects on Thyroid Cell Genes Mutated in the DNA Binding Site or at a Specific p 53 Updated (2006) (0)
and cell cycle (2007) (0)
Characterization of the Inflammatory Infiltrate of Ulcerative Dermatitis in Mice (2018) (0)
Contents Vol. 3, 2014 (2014) (0)
Retraction: High-Mobility Group A1 Proteins Regulate p53-Mediated Transcription of Bcl-2 Gene. (2018) (0)
PTC oncogenic signaling through the Rap 1 small GTPase (2013) (0)
Hmga2 is necessary for Otx2-dependent exit of embryonic stem cells from the pluripotent ground state (2016) (0)
Retraction: Haploinsufficiency of the Hmga1 Gene Causes Cardiac Hypertrophy and Myelo-Lymphoproliferative Disorders in Mice. (2018) (0)
Absence of Dedifferentiating and Transforming Effects Hormone-independent Proliferation of Thyroid Cells in the Akt / Protein Kinase B Promotes Survival and Updated (2000) (0)
Retraction for Melillo et al., “Critical Role of the HMGI(Y) Proteins in Adipocytic Cell Growth and Differentiation” (2018) (0)
Subject Index Vol. 3, 2014 (2014) (0)
Genechip Microarray analysis of pituitary adenomas developed by HMGA transgenic mice (2006) (0)
45th Annual Meeting of the Italian Cancer Society Bergamo, 9-12 November 2003 (2004) (0)
Molecular mechanisms of insulin resistance : role of endocannabinoid system in the regulation of glucose metabolism and insulin action ” (2007) (0)
Abstract 1386: Enhanced expression of HMGA1 and THY1 in human hepatocellular carcinoma correlates with poor prognosis (2014) (0)
Sulfate-binding Protein in Human Thyroid Carcinomas Gene Coding for a Heparin / Heparan HIP Overexpression of the Updated (2006) (0)
Publisher Correction: HMGA1-pseudogene7 transgenic mice develop B cell lymphomas (2021) (0)
Detection ofRET oncogeneactivation inhumanpapillary thyroid carcinomas byinsitu hybridisation (1992) (0)
Targeting of PATZ1 by miR-29b is a downstream effect of oncogenic Ras signalling in thyroid cells (2013) (0)
Retraction: Suppression of HMGA2 Protein Synthesis Could Be a Tool for the Therapy of Well Differentiated Liposarcomas Overexpressing HMGA2. (2018) (0)
Retraction for Fusco et al., “A mos Oncogene-Containing Retrovirus, Myeloproliferative Sarcoma Virus, Transforms Rat Thyroid Epithelial Cells and Irreversibly Blocks Their Differentiation Pattern” (2018) (0)
Retraction: FRA-1 Expression in Hyperplastic and Neoplastic Thyroid Diseases (2019) (0)
The Cooperation between Viral ras Genes and Different Immortalizing Genes Induces the Transformation of Rat Thyroid Epithelial Cells (1989) (0)
Supplemental Table 1: Studies Utilizing In Vitro Tube Formation Assay Manuscript Authors Reference Identifier Newly synthesized quinazolinone HMJ-38 suppresses angiogenetic responses and triggers human umbilical vein endothelial cell apoptosis through p53-modulated Fas/death receptor signaling. (2013) (0)
RETRACTED ARTICLE: Critical role of CCDC6 in the neoplastic growth of testicular germ cell tumors (2013) (0)
Abstract 4496: UBCH10 overexpression in human colorectal cancers (2012) (0)
The Activation of the Phosphotyrosine Phosphatase (cid:1) (r-PTP (cid:1) ) Is Responsible for the Somatostatin Inhibition of PC Cl3 Thyroid Cell Proliferation (2001) (0)
Precocious arrest of spermatogenesis in mice lacking PATZ gene. (2007) (0)
Erratum: CBX7 is a tumor suppressor in mice and humans (Journal of Clinical Investigation (2013) 123:2 (934) DOI: 10.1172/JCI68754) (2013) (0)
NEUTROPHIL (PMN) APOPTOSIS (Ao) IS MEDIATED BY THE CXC CHEMOKINE TYPE II RECEPTOR: IMPLICATION IN THE TREATMENT OF ARDS.: 220 (1998) (0)
Genes Mutated in the DNA Binding Site or at a Specific COOH-terminal Site Exert Divergent Effects on Thyroid Cell Growth and Differentiation 1 (2006) (0)
Gefitinib and Radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck ” (2008) (0)
Retraction Note: Critical role of CCDC6 in the neoplastic growth of testicular germ cell tumors (2021) (0)
DDX 3 X interaction controls the stability of Zc 3 h 12 a mRNA induced by IL-17 Somma Domenico (2009) (0)
Abstract 3195: HMGA1 and HMGA2 over-expression in human lung carcinoma (2011) (0)
Retraction Note: Critical role of CCDC6 in the neoplastic growth of testicular germ cell tumors (2021) (0)
Contents Vol. 4, 2015 (2015) (0)
New biomolecular prognostic and predictive factors of response to treatments in colorectal cancer ” (2010) (0)
PTC in thyroid tumours (1993) (0)
miR-155 is positively regulated by CBX7 in mouse embryonic fibroblasts and colon carcinomas, and targets the KRAS oncogene (2017) (0)
Retraction: The Receptor-Type Protein Tyrosine Phosphatase J Antagonizes the Biochemical and Biological Effects of RET-Derived Oncoproteins. (2018) (0)
Thymosin ÃŸ-10Gene Overexpression Correlated with the Highly Malignant Neoplastic Phenotype of Transformed Thyroid Cells in Vivo and in Vitro1 (2006) (0)
Leukemic Blasts From Patients With Acute Myeloid Leukemias (2005) (0)
INTERACTION BETWEEN THE INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR AND PDK 1 AS POTENTIAL THERAPEUTIC TARGET IN NEOPLASTIC CELLS ” (2007) (0)
ANew Somatostatin Analogue , Is Highly Effective in the Therapy of Growth Hormone / Prolactin-Secreting PituitaryAdenomas (2007) (0)
Inhibition of Heat Shock Protein 27 ( Hsp 27 ) sensitizes Non-Small Cell Lung Cancer Cells to Epidermal Growth Factor Receptor ( EGFR ) inhibitors ” (2016) (0)
MYELOPROLIFERATIVE DISEASE CHARACTERIZED BY THROMBOSIS, BLEEDING AND PLATELET DYSFUNCTION IN MICE INJECTED WITH THE POLYOMA MURINE LEUKEMIA VIRUS (PyMLV) (1987) (0)
Molecular and genetic alterations in human thyroid carcinomas (1997) (0)
The role of autophagy in neoplastic cell response to oncolytic viruses ” (2009) (0)
DNA-MEDIATED GENE TRANSFER AND EXPRESSION OF CLONED HERPES THYMIDINE KINASE AND HUMAN GLOBIN GENES IN MOUSE ERYTHROLEUKEMIC FRIEND CELLS (1981) (0)
HMGA 1 : a choice of symmetry (2015) (0)
RPSAP52 lncRNA is overexpressed in pituitary tumors and promotes cell proliferation by acting as miRNA sponge for HMGA proteins (2019) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Alfredo Fusco?

Alfredo Fusco is affiliated with the following schools:

Alfredo Fusco's Academic­Influence.com Rankings

Alfredo Fusco's Degrees

Similar Degrees You Can Earn

Why Is Alfredo Fusco Influential?

Alfredo Fusco's Published Works

Published Works

What Schools Are Affiliated With Alfredo Fusco?

Alfredo Fusco's AcademicInfluence.com Rankings